Epigenetically maintained SW13 and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibitionReportar como inadecuado

Epigenetically maintained SW13 and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 16:316

Cell and molecular biology


BackgroundThe BRM and BRG1 tumor suppressor genes are mutually exclusive ATPase subunits of the SWI-SNF chromatin remodeling complex. The human adrenal carcinoma SW13 cell line can switch between a subtype which expresses these subunits, SW13+, and one that expresses neither subunit, SW13-. Loss of BRM expression occurs post-transcriptionally and can be restored via histone deacetylase HDAC inhibition. However, most previously used HDAC inhibitors are toxic and broad-spectrum, providing little insight into the mechanism of the switch between subtypes. In this work, we explore the mechanisms of HDAC inhibition in promoting subtype switching and further characterize the oncogenic potential of the two epigenetically distinct SW13 subtypes.

MethodsSW13 subtype morphology, chemotaxis, growth rates, and gene expression were assessed by standard immunofluorescence, transwell, growth, and qPCR assays. Metastatic potential was measured by anchorage-independent growth and MMP activity. The efficacy of HDAC inhibitors in inducing subtype switching was determined by immunofluorescence and qPCR. Histone modifications were assessed by western blot.

ResultsTreatment of SW13- cells with HDAC1 inhibitors most effectively promotes re-expression of BRM and VIM, characteristic of the SW13+ phenotype. During treatment, hyperacetylation of histone residues and hypertrimethylation of H3K4 is pronounced. Furthermore, histone modification enzymes, including HDACs and KDM5C, are differentially expressed during treatment but several features of this differential expression pattern differs from that seen in the SW13- and SW13+ subtypes. As the SW13- subtype is more proliferative while the SW13+ subtype is more metastatic, treatment with HDACi increases the metastatic potential of SW13 cells while restoring expression of the BRM tumor suppressor.

ConclusionsWhen compared to the SW13- subtype, SW13+ cells have restored BRM expression, increased metastatic capacity, and significantly different expression of a variety of chromatin remodeling factors including those involved with histone acetylation and methylation. These data are consistent with a multistep mechanism of SW13- to SW13+ conversion and subtype stabilization: histone hypermodification results in the altered expression of chromatin remodeling factors and chromatin epigenetic enzymes and the re-expression of BRM which results in restoration of SWI-SNF complex function and leads to changes in chromatin structure and gene expression that stabilize the SW13+ phenotype.

KeywordsEpigenetic regulation Histone modification HDAC inhibitors Adrenocortical carcinoma SWI-SNF BRM Chromatin remodeling AbbreviationsBRD2bromodomain containing 2

BRG1 SMARCA4Brahma related gene 1


HDACihistone deacetylase inhibitor

KDM5Clysine K-specific demethylase 5C

MBD2methyl-CpG binding domain protein 2

SWI-SNFSWItch-Sucrose NonFermentable

TSAtrichostatin A

Electronic supplementary materialThe online version of this article doi:10.1186-s12885-016-2353-7 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: McKale R. Davis - Juliane J. Daggett - Agnes S. Pascual - Jessica M. Lam - Kathryn J. Leyva - Kimbal E. Cooper - Eliza

Fuente: https://link.springer.com/

Documentos relacionados